

Table 2.3. Case-control studies of combined estrogen-progestogen menopausal therapy and breast cancer

Reference, location, study period	Age (yrs)	Histology	Subset	Therapy type/regimen	Cases	Controls	Odds ratio	95% CI
Li <i>et al.</i> (2006), USA, 1994-1998	35-64	Invasive	All	Never	1116	731		
				Ever	1793	2029		
				Current E+P				
				Ductal	347		1.2	1.0-1.5
				Lobular	42		1.5	1.0-2.4
				Ductal-lobular	47		2.9	1.7-4.9
				Medullary	3		0.8	0.2-3.0
				Tubular	3.2		3.2	1.3-7.5
Rosenberg <i>et al.</i> (2006b), Sweden, 1993-95	50-74	Invasive	All ER+PR+	E + P [mainly estradiol + progestin]				
				Never	1854	1165	3.0	2.1-4.1
				All	771	2 384	1.0	
				Ever	261	409	2.0	1.6-2.4
				Current	177	289	1.9	1.5-2.4
				Exclusive use				
				Ever	182	306	1.8	1.5-2.3
				Duration				
				<5	98	201	1.4	1.1-1.9
				≥5	78	88	3.0	2.1-4.1
				Recency				
Current	131	191	2.2	1.7-2.8				
Past	45	98	1.4	1.0-2.0				

Table 2.3. Case-control studies of combined estrogen-progestogen menopausal therapy and breast cancer

Reference, location, study period	Age (yrs)	Histology	Subset	Therapy type/regimen	Cases	Controls	Odds ratio	95% CI
Rosenberg <i>et al.</i> (2006b) (contd)	50-74	Invasive	ER-PR-	Never	1854	332	1.3	0.7-2.5
				All	225	2384	1.0	
				Ever	66	409	1.4	1.0-1.9
				Current	41	289	1.2	0.8-1.8
				Exclusive use				
				Ever	44	306	1.3	0.9-1.8
				Duration				
				<5	29	201	1.2	0.8-1.8
				≥5	12	88	1.3	0.7-2.5
				Recency				
			Current	26	191	1.1	0.7-1.8	
			Past	15	98	1.4	0.8-2.5	
			E + P [medium potency]					
			Never	2289	3065			
			Ever	1061	1707			
			Ductal	All	1888	71	2.3	1.6-3.3
				Never	903	1707		
				Ever	320	350	1.6	1.3-1.9
				Current	208	222	1.7	1.3-2.1
				Duration				
<5	137	160		1.4	1.1-1.8			
≥5	71	62		2.3	1.6-3.3			
Recency								
Current				2.0	1.5-2.5			
Past				1.0	0.7-1.5			
Sequential								
<5	63	56	1.9	1.3-2.8				
≥5	16	15	2.1	1.0-4.3				
Recency								
Current			2.9	1.8-4.6				

Table 2.3. Case-control studies of combined estrogen-progestogen menopausal therapy and breast cancer

Reference, location, study period	Age (yrs)	Histology	Subset	Therapy type/regimen	Cases	Controls	Odds ratio	95% CI
Rosenberg <i>et al.</i> (2006b) (contd)			Lobular	All	308	21	5.6	3.2–9.7
				Never	121	1707		
				Ever	79	350	3.2	2.3–4.4
				Current	43	222	2.8	1.8–4.2
				Duration				
				<5	22	160	1.8	1.1–3.1
				≥5	21	62	5.6	3.2–9.7
				Recency				
				Current			3.3	2.1–5.3
				Past			1.6	0.7–3.6
				Sequential				
				<5	7	56	1.7	0.8–4.1
				≥5	3	15	3.4	0.9–12.1
				Recency				
			Current			2.9	1.2–7.1	
			Tubular	All	93	9	6.5	2.8–14.9
				Never	37	1707		
				Ever	32	359	4.1	2.4–7.0
				Current	16	222	3.3	1.7–6.4
				Duration				
				<5	7	160	1.9	0.8–4.7
				≥5	6	62	6.5	2.8–14.9
		Recency						
		Current				4.2	2.1–8.8	
		Past				1.4	0.3–6.1	
		Sequential						
		<5	4	56	2.8	0.9–9.0		
		≥5	1	15	2.7	0.3–21.7		
		Recency						
		Current			4.6	1.4–15.8		

Table 2.3. Case-control studies of combined estrogen-progestogen menopausal therapy and breast cancer

Reference, location, study period	Age (yrs)	Histology	Subset	Therapy type/regimen	Cases	Controls	Odds ratio	95% CI
Wu et al. (2006), Los Angeles County, USA , 1995-2001	25-74	31% regional/metastatic cancer	All	EPT [estrogen and progestin]	1277	1160		
				Never/short term	423	343		
				Former				
				≥1 to <5	22	18	1.15	0.58-2.29
				≥5 yrs	24	13	1.51	0.69-3.31
				Current E+P				
				Duration				
				≥1 to <5	62	49	1.06	(0.67-1.67)
				≥5 to >10	50	33	1.41	(0.83-2.37)
				≥10	33	11	2.59	(1.20-5.60)
			Chinese	450	486			
			Japanese	352	311			
			Filipino	475	363			